Millets and Blood Sugar: What the Research Shows

What the numbers actually say

Glycemic index (GI) measures how fast a food raises your blood sugar after you eat it. Millets, as a group, average a GI of 52.7 — low enough to count as "low GI" (under 55), or just at the low end of "medium GI" (55–69). That's a real gap from white rice and refined wheat flour, which usually sit well above that.

But not every millet is the same. The same review found foxtail millet, barnyard millet, and job's tears at the lower end, while pearl millet, ragi, kodo millet, little millet, and sorghum sit a bit higher, in the medium range. So "millets are low-GI" is a fair general statement, but if you're making a specific claim about a specific product, it matters which millet is actually in it. A snack made with foxtail millet flour and one made with sorghum flour aren't making quite the same nutritional promise, even if both can honestly say "millet-based" on the label.

The blood-sugar findings — not just the GI number

GI is measured in a lab test — it doesn't automatically tell you what happens in someone's body over weeks of actually eating the food. That's why the more useful part of this review is what happened when people ate millet regularly over time: fasting and after-meal blood sugar dropped by roughly 12–15%, and some people moved from a diabetic to a pre-diabetic range over the course of the studies.

HbA1c is a blood marker that reflects your average blood sugar over about three months — doctors generally trust it more than a single glucose reading, since it isn't thrown off by whatever you happened to eat that day. Among pre-diabetic people in the pooled studies, HbA1c improved by 17% on average. Having both a genuinely lower GI and a measurable real-world effect over time is why this particular review gets cited more than one-off studies — the two findings back each other up.

Why the specific millet matters

GI varies a fair amount across the nine major millets — roughly from the low 40s to the high 60s. That means "low glycemic index" is a safe thing to say about millets as a category, but a riskier thing to promise about one specific product without knowing exactly which millet it uses, and how it was processed. Whole-grain millet and finely milled millet flour don't necessarily behave the same way — grinding a grain down tends to raise its glycemic effect, which is a well-known pattern across cereals generally, not something unique to this study.

For processors deciding how finely to mill a batch, that's a real trade-off: finer flour usually makes for better texture in packaged snacks, but it can work against the low-GI story that made millets attractive in the first place. There's no published number for exactly how much GI shifts with milling fineness for each millet — that's simply a gap in the current research, not something this review covered — but it's worth knowing if you're building a product around a glycemic-index claim.

What this evidence doesn't prove

It's worth being honest about the limits here. This is a review that pools together many smaller studies, not one big, tightly-controlled trial. That kind of review is genuinely useful for spotting a real pattern, but it carries more uncertainty than a single well-designed study would — 65 different studies also means 65 different groups of people, methods, and definitions of "regular consumption" being lumped together, which is a normal limitation of this kind of research, not a flaw specific to this one.

The research supports millets as part of a diet that's friendly to blood sugar. It does not make millets a diabetes treatment, and none of it should replace a diagnosis, a monitoring plan, or a treatment decision made with a doctor. Anyone using this research in marketing should keep that line clear.

Why this matters for the industry, not just for shoppers

For processors and brands, this evidence is solid enough to support honest, specific claims about glycemic index — but claiming millets treat or cure diabetes would be both scientifically wrong and, in most markets, a compliance problem. The claim that holds up is comparative and dietary — "lower glycemic index than rice and wheat, as part of a balanced diet" — not medical. Staying on that side of the line matters both for getting the science right and for FSSAI-compliant packaging claims.